UnitedHealth Just Proved Warren Buffett Right -- Again

UnitedHealth reported better-than-expected Q1 revenue and earnings, and raised full-year earnings guidance, signaling an early turnaround. Its medical cost ratio improved to 83.9% from 84.8% as the company implemented higher rates, helping offset persistently elevated utilization. The article frames Warren Buffett's $1.6 billion stake as validated by the quarter's results, despite prior CEO turnover and DOJ scrutiny.

Analysis

UNH’s quarter matters less as a one-off earnings beat than as evidence that pricing power is still the dominant variable in managed care. The important second-order effect is that when utilization stays elevated but pricing resets lag with a quarter or two of delay, the profit pool is not destroyed — it is reallocated across time, which usually favors the largest insurers with the best underwriting data, contracting leverage, and ability to re-price faster than smaller peers.

The market is also underestimating how quickly sentiment can re-rate once the “regulatory overhang” becomes less acute. CMS volatility was a catalyst for multiple compression rather than a true earnings impairment; if reimbursement outcomes normalize, the stock can recover on a mix of estimate revisions and lower risk premium, not just better fundamentals. That argues the upside is more durable than a simple post-earnings pop, but the path remains choppy because the next leg depends on whether medical cost trends stabilize by the next two reporting cycles.

The contrarian risk is that investors extrapolate one clean quarter into a full turnaround before the cost curve has actually rolled over. If utilization remains structurally high into 2H, management may have to choose between further premium actions and some volume pressure in certain segments, which would cap near-term margin expansion. In other words, the thesis is not “costs are falling”; it is “rates are catching up,” and that distinction matters if another reimbursement shock, legal headline, or administrative intervention hits before pricing fully resets.

BRK.B’s role is more indirect but still important: this is another data point validating Buffett’s willingness to buy earnings volatility when balance-sheet durability is intact. The broader implication for the market is that defensive compounders with temporary headline damage remain mispriced relative to their normalized earnings power, especially when passive flows and litigation-driven de-risking create forced selling. That should keep putting a floor under quality names in healthcare even if the sector’s multiples stay range-bound.

Key Decisions for Investors

• Long UNH vs. short managed-care basket hedge (e.g., short smaller-cap insurers or an equal-weight healthcare payer basket) for a 3-6 month horizon; thesis is that scale and pricing power let UNH normalize margins faster than peers if utilization stays elevated.
• Buy UNH on pullbacks rather than strength; target entry after any post-earnings fade or regulatory headline-driven selloff, with a 6-12 month view and upside driven by multiple re-rating plus guide raises.
• Use call spreads in UNH for defined risk over the next 2 earnings cycles; the setup is asymmetric if pricing actions continue to offset medical cost pressure, but downside should be capped because the core business is not impaired.
• Stay underweight CMS-sensitive healthcare names with weaker contracting leverage until reimbursement visibility improves; the risk/reward is poor if rate assumptions reset again over the next 1-2 quarters.
• Hold BRK.B as a lower-volatility expression of the same quality-under-distinctions theme; if the market continues rewarding balance-sheet strength and patience, Berkshire remains the cleaner way to express the Buffett-style compounder factor.